文献速递膀胱癌与上尿路尿路上皮癌

新型经尿道机器人平台用于膀胱肿瘤整块切除:VIABLE试验第一阶段结果

A Novel Transurethral Robotic Platform for Performing En Bloc Resection of Bladder Tumour: Results from the First Phase of the VIABLE Trial.
PubMed 文献 · Eur Urol Oncol · 2025-11-22

VIABLE试验首次在人体中评估Virtuoso内镜系统(VES)经尿道切除膀胱病变的可行性,6例患者共12个膀胱病变均成功完成整块或改良整块切除,无术中不良事件,2例出现术后不良事件(33%),无膀胱穿孔、30天再手术或死亡。

要点

  • VES成功完成所有6例患者12个膀胱病变的整块或改良整块切除。
  • 所有病变标本均含逼尿肌,实现准确分期,91%标本切缘可评估。
  • 无术中不良事件、膀胱穿孔、30天再手术或死亡,术后不良事件33%。

核心结论

  • VES经尿道整块切除膀胱病变在首个人体研究中显示可行,所有病变均成功切除且无术中并发症。

研究设计与样本

  • 首次人体研究,纳入6例患者共12个膀胱病变,评估VES经尿道切除的安全性和有效性。

主要发现

  • 所有12个膀胱病变(100%)经整块或改良整块技术切除,平均手术时间52±20分钟。
  • 所有膀胱病变(100%)标本含逼尿肌,实现准确分期;91%标本切缘可评估。
  • 无术中不良事件或并发症;2例患者(33%)出现术后不良事件,包括1例需保守治疗的尿潴留(1级)和1例继发于新诊断食管肿瘤气管侵犯的胸部感染。
  • 无膀胱穿孔、30天再手术或30天死亡事件。

临床怎么用

  • VES可作为经尿道膀胱肿瘤整块切除的可行机器人平台,但需进一步试验验证其临床获益。

局限性

  • 首次人体研究样本量小(6例患者12个病变),为第一阶段可行性评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Virtuoso Endoscopy System (VES) is a novel robotic surgical system designed for transurethral excision of bladder lesions. In this first-in-human study, we evaluated the feasibility of using the VES to perform safe and effective excision in six patients with 12 bladder lesions. VES excision of bladder lesions was successful in all six patients, and all 12 bladder lesions (100%) were excised via an en bloc or modified en bloc technique. The mean procedural time was 52 ± 20 min. None of the patients required conversion to standard equipment for bladder lesion resection. Accurate staging, defined as the presence of detrusor muscle in the specimen, was achieved for all bladder lesions (100%). Evaluable margins were present in 91% of the bladder lesion specimens. None of the patients developed any intraoperative adverse events or complications. Two patients had postoperative adverse events (33%). One case of postoperative urinary retention (grade 1) resolved after conservative management. One case of chest infection was later found to be secondary to a newly diagnosed oesophageal tumour with tracheal invasion. There were no bladder perforations, any 30-d reoperations, or 30-d mortality events. The trial is registered on ClinicalTrials.gov as NCT06940648.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Teoh JY, Bracco FM, Wong JH, et al. A Novel Transurethral Robotic Platform for Performing En Bloc Resection of Bladder Tumour: Results from the First Phase of the VIABLE Trial. Eur Urol Oncol. 2025. PMID: 41276423. doi:10.1016/j.euo.2025.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。